Is UnitedHealth Group Incorporated (UNH) A Good Stock To Buy Now?

<p>Is UNH a good stock to buy? We came across a <a href="https://investomine.substack.com/p/unitedhealth-group-a-reset-year-not">bullish thesis </a>on UnitedHealth Group Incorporated on Investomine’s Substack. In this article, we will summarize the bulls’ thesis on UNH. UnitedHealth Group Incorporated's share was trading at $285.17 as of March 9th. UNH’s trailing and forward P/E were 21.65 and 16.13, respectively according to Yahoo Finance.</p>
<p>UnitedHealth Group Incorporated operates as a health care company in the United States and internationally. UNH experienced a turbulent 2025, with headline margins collapsing and investor confidence shaken, but beneath these short-term pressures, the company’s structural advantages remain intact.</p>
<p>Revenue reached $447.6 billion, up 12% year-over-year, yet GAAP EPS fell to $13.23 and adjusted EPS to $16.35, reflecting a net margin of just 2.7%. The earnings compression was driven primarily by Medicare reimbursement cuts, IRA impacts on Part D, elevated medical costs, and one-time charges including cyberattack responses and restructuring.</p>
<p>UnitedHealthcare, the company’s largest segment, reported $344.9 billion in revenue, serving nearly 50 million members, but operating margins declined from 5.2% to 2.7%. This was not due to volume loss—Medicare Advantage membership grew by 755,000—but rather pricing discipline lagging rising costs, which management has addressed through 2026 repricing initiatives. Optum, UNH’s diversified platform, displayed a mixed picture: Optum Rx generated $154.7 billion in revenue with $7.2 billion in operating earnings, continuing to compound earnings, while Optum Insight maintained a 22% margin, reinforcing UNH’s data-driven moat.</p>
<p>Optum Health underperformed with a $278 million operating loss due to loss contracts and elevated utilization, but management has re-baselined the segment and targets margin recovery in 2026. Strong operating cash flow of $19.7 billion, a disciplined balance sheet, and prudent capital allocation underscore UNH’s resilience.</p>
<p>2026 guidance is conservative, with adjusted EPS above $17.75 and margins recovering to ~5.5%, driven by repricing, cost control, and Optum normalization. While risks remain from policy, medical inflation, and Optum Health execution, UNH represents a structurally advantaged healthcare platform undergoing a temporary reset, offering long-term investors an attractive opportunity at current sentiment levels.</p>
<p>Previously, we covered a <a href="https://www.insidermonkey.com/blog/unitedhealth-group-incorporated-unh-a-bull-case-theory-3-1542416/">bullish thesis</a> on UnitedHealth Group Incorporated (UNH) by FluentInQuality in May 2025, which highlighted its scale, provider network, Optum integration, and strong U.S. healthcare tailwinds. UNH’s stock price has depreciated by approximately 3.33% since our coverage. Investomine shares a similar view but focuses on the 2025 earnings reset, margin pressures, and Optum Health normalization in 2026.</p>